Author:
Zhang Jianming,Adrián Francisco J.,Jahnke Wolfgang,Cowan-Jacob Sandra W.,Li Allen G.,Iacob Roxana E.,Sim Taebo,Powers John,Dierks Christine,Sun Fangxian,Guo Gui-Rong,Ding Qiang,Okram Barun,Choi Yongmun,Wojciechowski Amy,Deng Xianming,Liu Guoxun,Fendrich Gabriele,Strauss André,Vajpai Navratna,Grzesiek Stephan,Tuntland Tove,Liu Yi,Bursulaya Badry,Azam Mohammad,Manley Paul W.,Engen John R.,Daley George Q.,Warmuth Markus,Gray Nathanael S.
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Weisberg, E. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129–141 (2005)
2. Quintas-Cardama, A., Kantarjian, H. & Cortes, J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nature Rev. Drug Discov. 6, 834–848 (2007)
3. Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399–401 (2004)
4. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001)
5. Nagar, B. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236–4243 (2002)
Cited by
520 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献